The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Jim Cramer recommends buying Stryker Corp and holding long term
Jim Cramer has recommended Stryker Corp (SYK) as a buy, advising investors to adopt a long-term perspective and "forget about it." This suggests confidence in the company's future performance and stability in the market.
Top Health Care Stocks to Consider for Investment in 2025
Amgen's MariTide obesity drug showed mid-stage trial results in line with competitors, while Stryker's Mako robotic product and outpatient focus position it as a strong investment. Pfizer's potential divestment of its hospital drugs business could enhance its core growth, and Boston Scientific's promising pipeline supports its long-term outlook. CFRA maintains "buy" ratings for these companies, with specific price targets reflecting their growth potential.